{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:48:07Z","timestamp":1779886087204,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:00:00Z","timestamp":1346976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The vitamin D receptor activator paricalcitol has been shown to reduce albuminuria. Whether this is a unique property of paricalcitol, or common to all vitamin D analogues, is unknown. The primary aim of this study was to evaluate the effect of alfacalcidol on proteinuria, measured as 24\u2009hour (24\u2009h) albuminuria, in patients with chronic kidney disease (CKD) stage 4\u20135 being treated for secondary hyperparathyroidism (sHPT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective single-center study including adult patients with CKD 4\u20135, undergoing treatment for sHPT with alfacalcidol, with macroalbuminuria in minimum one 24\u2009h urine collection. Patients were identified in a prospectively collected database of all patients with S-creatinine &gt; 300\u2009\u03bcM or creatinine clearance &lt; 30\u2009ml\/min. The observation period was from 1<jats:sup>st<\/jats:sup> of January 2005 to 31<jats:sup>st<\/jats:sup> of December 2009. Phosphate binders and alfacalcidol were provided to patients free of charge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 146 macroalbuminuric patients were identified, and of these, 59 started alfacalcidol treatment during the observation period. A 12% reduction in 24\u2009h albuminuria was seen after starting treatment. In 19 patients with no change in renin-angiotensin-aldosteron-system (RAAS) inhibition, the reduction in albuminuria was 16%. The reduction remained stable over time (9%) in a subgroup of patients (n = 20) with several urine collections before and after the start of alfacalcidol-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The present study supports experimental and clinical data on antiproteinuric actions of activated vitamin D analogues, and suggests that this may be a class-effect.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-13-102","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T10:15:07Z","timestamp":1347012907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4\u20135: a retrospective single center study"],"prefix":"10.1186","volume":"13","author":[{"given":"Hanne Skou","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Winther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Vestergaard","family":"Povlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ivarsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,7]]},"reference":[{"issue":"Suppl 3","key":"344_CR1","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.2215\/CJN.04331206","volume":"3","author":"SM Moe","year":"2008","unstructured":"Moe SM, Drueke T: Improving global outcomes in mineral and bone disorders. Clinical journal of the American Society of Nephrology : CJASN. 2008, 3 (Suppl 3): S127-S130.","journal-title":"Clinical journal of the American Society of Nephrology : CJASN"},{"issue":"6","key":"344_CR2","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Perna A, Remuzzi G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003, 63 (6): 2254-2261. 10.1046\/j.1523-1755.2003.00033.x.","journal-title":"Kidney Int"},{"issue":"2","key":"344_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","volume":"54","author":"AS Levey","year":"2009","unstructured":"Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2009, 54 (2): 205-226. 10.1053\/j.ajkd.2009.04.029.","journal-title":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"issue":"10","key":"344_CR4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00125-005-1893-1","volume":"48","author":"G Boner","year":"2005","unstructured":"Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, et al: Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia. 2005, 48 (10): 1980-1987.","journal-title":"Diabetologia"},{"key":"344_CR5","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1111\/j.1523-1755.2004.09221.x","volume":"92","author":"G Remuzzi","year":"2004","unstructured":"Remuzzi G, Chiurchiu C, Ruggenenti P: Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl. 2004, 92: S90-S96.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"344_CR6","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005, 68 (6): 2823-2828. 10.1111\/j.1523-1755.2005.00755.x.","journal-title":"Kidney Int"},{"issue":"2","key":"344_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","volume":"52","author":"P Alborzi","year":"2008","unstructured":"Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008, 52 (2): 249-255. 10.1161\/HYPERTENSIONAHA.108.113159.","journal-title":"Hypertension"},{"issue":"4","key":"344_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","volume":"54","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N: Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2009, 54 (4): 647-652. 10.1053\/j.ajkd.2009.04.036.","journal-title":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"issue":"9752","key":"344_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D de Zeeuw","year":"2010","unstructured":"de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010, 376 (9752): 1543-1551. 10.1016\/S0140-6736(10)61032-X.","journal-title":"Lancet"},{"issue":"1","key":"344_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","volume":"59","author":"LJ Liu","year":"2012","unstructured":"Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY: Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2012, 59 (1): 67-74. 10.1053\/j.ajkd.2011.09.014.","journal-title":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"issue":"4","key":"344_CR11","doi-asserted-by":"publisher","first-page":"c268","DOI":"10.1159\/000276579","volume":"114","author":"H Reichel","year":"2010","unstructured":"Reichel H: Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. Nephron Clin Pract. 2010, 114 (4): c268-c276. 10.1159\/000276579.","journal-title":"Nephron Clin Pract"},{"issue":"8","key":"344_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/ki.2011.226","volume":"80","author":"D Hansen","year":"2011","unstructured":"Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, et al: No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int. 2011, 80 (8): 841-850. 10.1038\/ki.2011.226.","journal-title":"Kidney Int"},{"issue":"2","key":"344_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ki.1991.202","volume":"40","author":"S Matthias","year":"1991","unstructured":"Matthias S, Busch R, Merke J, Mall G, Thomasset M, Ritz E: Effects of 1,25(OH)2D3 on compensatory renal growth in the growing rat. Kidney Int. 1991, 40 (2): 212-218. 10.1038\/ki.1991.202.","journal-title":"Kidney Int"},{"issue":"6","key":"344_CR14","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1046\/j.1523-1755.1998.00951.x","volume":"53","author":"U Schwarz","year":"1998","unstructured":"Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998, 53 (6): 1696-1705. 10.1046\/j.1523-1755.1998.00951.x.","journal-title":"Kidney Int"},{"issue":"1","key":"344_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1523-1755.2001.00775.x","volume":"60","author":"V Panichi","year":"2001","unstructured":"Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, et al: Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001, 60 (1): 87-95. 10.1046\/j.1523-1755.2001.00775.x.","journal-title":"Kidney Int"},{"issue":"5","key":"344_CR16","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0002-9440(10)64129-6","volume":"158","author":"K Makibayashi","year":"2001","unstructured":"Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, et al: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol. 2001, 158 (5): 1733-1741. 10.1016\/S0002-9440(10)64129-6.","journal-title":"Am J Pathol"},{"issue":"3","key":"344_CR17","doi-asserted-by":"publisher","first-page":"F526","DOI":"10.1152\/ajprenal.00316.2003","volume":"286","author":"A Kuhlmann","year":"2004","unstructured":"Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol. 2004, 286 (3): F526-F533. 10.1152\/ajprenal.00316.2003.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"344_CR18","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1681\/ASN.2006091028","volume":"18","author":"M Mizobuchi","year":"2007","unstructured":"Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al: Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. Journal of the American Society of Nephrology : JASN. 2007, 18 (6): 1796-1806. 10.1681\/ASN.2006091028.","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"2","key":"344_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.ki.5002572","volume":"73","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008, 73 (2): 163-171. 10.1038\/sj.ki.5002572.","journal-title":"Kidney Int"},{"issue":"41","key":"344_CR20","doi-asserted-by":"publisher","first-page":"15896","DOI":"10.1073\/pnas.0803751105","volume":"105","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA. 2008, 105 (41): 15896-15901. 10.1073\/pnas.0803751105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"344_CR21","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/ki.2008.408","volume":"74","author":"M Freundlich","year":"2008","unstructured":"Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, et al: Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008, 74 (11): 1394-1402. 10.1038\/ki.2008.408.","journal-title":"Kidney Int"},{"issue":"3","key":"344_CR22","doi-asserted-by":"publisher","first-page":"F791","DOI":"10.1152\/ajprenal.00247.2009","volume":"297","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, et al: Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009, 297 (3): F791-F801. 10.1152\/ajprenal.00247.2009.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"344_CR23","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1093\/ndt\/gfp117","volume":"24","author":"I Matsui","year":"2009","unstructured":"Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, et al: Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2009, 24 (8): 2354-2361. 10.1093\/ndt\/gfp117.","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"11","key":"344_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ki.2010.22","volume":"77","author":"DK Deb","year":"2010","unstructured":"Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, et al: Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010, 77 (11): 1000-1009. 10.1038\/ki.2010.22.","journal-title":"Kidney Int"},{"issue":"4","key":"344_CR25","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1159\/000320284","volume":"117","author":"I Ohara","year":"2011","unstructured":"Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, et al: Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)\/Ta mice. Nephron Exp Nephrol. 2011, 117 (4): e124-e132. 10.1159\/000320284.","journal-title":"Nephron Exp Nephrol"},{"issue":"1","key":"344_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000334626","volume":"35","author":"A Lydia","year":"2012","unstructured":"Lydia A, Asanuma K, Nonaka K, Takagi M, Jeong KH, Kodama F, et al: Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis. Am J Nephrol. 2012, 35 (1): 58-68. 10.1159\/000334626.","journal-title":"Am J Nephrol"},{"issue":"1","key":"344_CR27","doi-asserted-by":"publisher","first-page":"F141","DOI":"10.1152\/ajprenal.00293.2011","volume":"302","author":"JL Finch","year":"2012","unstructured":"Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ, et al: Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol. 2012, 302 (1): F141-F149. 10.1152\/ajprenal.00293.2011.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"344_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/JCI0215219","volume":"110","author":"YC Li","year":"2002","unstructured":"Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002, 110 (2): 229-238.","journal-title":"J Clin Invest"},{"issue":"12","key":"344_CR29","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1681\/ASN.2006050520","volume":"17","author":"X Tan","year":"2006","unstructured":"Tan X, Li Y, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. Journal of the American Society of Nephrology : JASN. 2006, 17 (12): 3382-3393. 10.1681\/ASN.2006050520.","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"5","key":"344_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1053\/j.ajkd.2007.12.038","volume":"51","author":"CC Szeto","year":"2008","unstructured":"Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK: Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2008, 51 (5): 724-731. 10.1053\/j.ajkd.2007.12.038.","journal-title":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"issue":"4","key":"344_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"J McMurray","year":"2012","unstructured":"McMurray J, Abraham W, Dickstein T, K\u00f8ber L, Massie B, Krum AH: ALTITUDE and the implications for ATMOSPHERE. Eur J Heart Fail. 2012, 14 (4): 341-343. 10.1093\/eurjhf\/hfs033.","journal-title":"Eur J Heart Fail"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-13-102\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:59:02Z","timestamp":1630526342000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-13-102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-13-102","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,7]]},"assertion":[{"value":"12 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"102"}}